KRAS and familial pancreatic carcinoma: In an effort to verify the pancreatic cancer identity of the three CTC-derived cell lines, we evaluated the KRAS mutation status of our cell lines and detected a heterozygous G12/G13 mutation in all three CTC cell lines.